Next-Generation Stem Cell Therapy
induced monocyte progenitors (iMoP)
The generation of autologous monocyte progenitors (MoPs) can offer therapeutic benefits in animal model of various inflammatory diseases. Our direct conversion technology enables the large production of highly pure self-renewing iMoPs from somatic cells. iMoPs exhibit the hallmarks of bona fide monocyte progenitor cells, including cellular morphology, marker expression, and immune response.
Characteristics and Functionality
Generation of self-renewing iMoPs
iMoPs show typical round-shape morphology and homogenously express monocyte progenitor markers; CD11b, CD45, Iba-1, and CX3CR.
Phagocytosis of green fluorescence-labeled beads (green) by iMOPs stained with macrophage marker (F4/80). Cells were activated by treating LPS to induce phagocytosis
Transplantation of iMoP derived M2 macrophages in inflammatory bowel disease(IBD) model in vivo rescued colitis severity.
AddressHeadquarters : (44919) 105 Stem cell research center, 50, UNIST-gil, Eonyang-eup, Ulju-gun, Ulsan, Republic of KoreaSeoul office : (06180) 518, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea
Tel 052-217-5274 E-mailinfo@supinetherapeutics.com
COPYRIGHT BY SUPINE THERAPEUTICS. ALL RIGHTS RESERVED.